Definitive Healthcare Corp. (DH)
| Market Cap | 94.87M |
| Revenue (ttm) | 238.26M |
| Net Income (ttm) | -170.33M |
| Shares Out | 143.75M |
| EPS (ttm) | -1.63 |
| PE Ratio | n/a |
| Forward PE | 3.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,199,233 |
| Open | 0.640 |
| Previous Close | 0.628 |
| Day's Range | 0.620 - 0.679 |
| 52-Week Range | 0.620 - 4.700 |
| Beta | 1.33 |
| Analysts | Buy |
| Price Target | 2.67 (+304.55%) |
| Earnings Date | Aug 6, 2026 |
About DH
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company’s platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician... [Read more]
Financial Performance
In 2025, Definitive Healthcare's revenue was $241.52 million, a decrease of -4.24% compared to the previous year's $252.20 million. Losses were -$138.93 million, -66.37% less than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for DH stock is "Buy." The 12-month stock price target is $2.67, which is an increase of 304.55% from the latest price.
News
Restaurant365 Names Kate Hastings Chief Customer Officer as It Expands Investment in Customer Success
Customer success leader joins executive team to help restaurant operators accelerate value realization, adoption, and business outcomes. IRVINE, Calif.
Definitive Healthcare advances data platform and integrations to deliver smarter healthcare insights
Latest enhancements provide deeper medical claims insights, a new integration with HubSpot®, seamless access to healthcare professional (HCP) data directly in Salesforce, and AI search capabilities La...
Definitive Healthcare price target lowered to $1.10 from $1.30 at Baird
Baird lowered the firm’s price target on Definitive Healthcare (DH) to $1.10 from $1.30 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
Definitive Healthcare reports Q1 adjusted EPS 6c, consensus 3c
Reports Q1 revenue $55.93M, consensus $54.98M. “Definitive Healthcare (DH) started 2026 on a solid note, with financial results at or above the high end of our guidance ranges. We continue…
Definitive Healthcare sees Q2 adjusted EPS 3c-4c, consensus 4c
Sees Q2 revenue $55M-$56M, consensus $55.47M.
Definitive Healthcare raises FY26 adjusted EPS view to 16c-19c from 14c-17c
Consensus 17c. Backs FY26 revenue view $220M-$226M, consensus $223.64M. Backs FY26 adjusted EBITDA view $13.5M-$14.5M.
Definitive Healthcare Earnings Call Transcript: Q1 2026
Q1 2026 results were at or above guidance, with revenue down 6% year-over-year and strong margin expansion. Provider and diversified segments grew, offsetting life sciences declines, while AI and integration investments are expected to drive future growth.
Definitive Healthcare Slides: Q1 2026
Definitive Healthcare has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Definitive Healthcare Earnings release: Q1 2026
Definitive Healthcare released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Definitive Healthcare Quarterly report: Q1 2026
Definitive Healthcare has published its Q1 2026 quarterly earnings report on May 7, 2026.
Definitive Healthcare Reports Financial Results for First Quarter 2026
FRAMINGHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, tod...
Definitive Healthcare Announces Timing of Its First Quarter 2026 Financial Results Conference Call and Webcast
FRAMINGHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced th...
Definitive Healthcare Proxy statement: Proxy filing
Definitive Healthcare filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Definitive Healthcare Proxy statement: Proxy filing
Definitive Healthcare filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Definitive Healthcare price target lowered to $1 from $2.75 at Barclays
Barclays lowered the firm’s price target on Definitive Healthcare (DH) to $1 from $2.75 and keeps an Underweight rating on the shares. The firm updated models in healthcare technology to…
Definitive Healthcare price target lowered to $3 from $6 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Definitive Healthcare (DH) to $3 from $6 and keeps a Hold rating on the shares.
Definitive Healthcare price target lowered to $1.90 from $3 at Baird
Baird lowered the firm’s price target on Definitive Healthcare (DH) to $1.90 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results.
Definitive Healthcare price target lowered to $3 from $5 at Stifel
Stifel lowered the firm’s price target on Definitive Healthcare (DH) to $3 from $5 and keeps a Buy rating on the shares.
Definitive Healthcare price target lowered to $2 from $3 at Stephens
Stephens lowered the firm’s price target on Definitive Healthcare (DH) to $2 from $3 and keeps an Equal Weight rating on the shares. Turnaround efforts should drive Life Sciences revenue…
Definitive Healthcare price target lowered to $2 from $3 at Stephens
Stephens lowered the firm’s price target on Definitive Healthcare (DH) to $2 from $3 and keeps an Equal Weight rating on the shares. Turnaround efforts should drive Life Sciences revenue…
Definitive Healthcare price target lowered to $3 from $4 at Canaccord
Canaccord lowered the firm’s price target on Definitive Healthcare (DH) to $3 from $4 and keeps a Hold rating on the shares. The firm said they reported Q4 results that…
Definitive Healthcare reports Q4 adjusted EPS 6c, consensus 6c
Reports Q4 revenue $61.5M, consensus $59.57M. “Our fourth quarter results were at or above the high end of our guidance ranges on both the top and bottom line, demonstrating the…
Definitive Healthcare sees Q1 adjusted EPS 3c, consensus 6c
Sees Q1 revenue $54.0M-$56.0M, consensus $57.23M.
Definitive Healthcare sees FY26 adjusted EPS 14c-17c, consensus 26c
Sees FY26 revenue $220.0M-$226.0M, consensus $233.61M.
Definitive Healthcare Earnings Call Transcript: Q4 2025
Q4 revenue and profitability exceeded guidance despite a 1% year-over-year revenue decline, with strong cash flow and margin expansion. Retention rates improved, claims data volumes were restored, and diversified/provider segments returned to growth, while 2026 guidance reflects continued top-line pressure but improved operational execution.